Evaluation of the safety and tolerability of re-dosing with intravenous (iv) otelixizumab in newly diagnosed adult subjects with type 1 diabetes mellitus.
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 17 Jun 2011 Actual initiation date (Nov 2010) added as reported by ClinicalTrials.gov.